Literature DB >> 11061276

Rituximab for myasthenia gravis developing after bone marrow transplant.

F Zaja1, D Russo, G Fuga, G Perella, M Baccarani.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 11061276     DOI： 10.1212/wnl.55.7.1062-a

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


× No keyword cloud information.
  17 in total

1.  Practical considerations on the use of rituximab in autoimmune neurological disorders.

Authors:  Mixalis L Kosmidis; Marinos C Dalakas
Journal:  Ther Adv Neurol Disord       Date:  2010-03       Impact factor: 6.570

2.  Complete remission induced by rituximab in refractory, seronegative, muscle-specific, kinase-positive myasthenia gravis.

Authors:  William S Baek; Asad Bashey; Geoffrey L Sheean
Journal:  J Neurol Neurosurg Psychiatry       Date:  2007-07       Impact factor: 10.154

Review 3.  Therapies Directed Against B-Cells and Downstream Effectors in Generalized Autoimmune Myasthenia Gravis: Current Status.

Authors:  Grayson Beecher; Brendan Nicholas Putko; Amanda Nicole Wagner; Zaeem Azfer Siddiqi
Journal:  Drugs       Date:  2019-03       Impact factor: 9.546

4.  Pro: Should all patients with anti-neutrophil cytoplasmic antibody-associated vasculitis be primarily treated with rituximab?

Authors:  Ulrich Specks
Journal:  Nephrol Dial Transplant       Date:  2015-05-21       Impact factor: 5.992

Review 5.  Novel functions of B cells in transplantation.

Authors:  Jeffrey L Platt; Shoichiro Tsuji; Marilia Cascalho
Journal:  Curr Opin Organ Transplant       Date:  2011-02       Impact factor: 2.640

6.  Treatment of IgM antibody associated polyneuropathies using rituximab.

Authors:  A Pestronk; J Florence; T Miller; R Choksi; M T Al-Lozi; T D Levine
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-04       Impact factor: 10.154

7.  Reactivation of latent viruses in individuals receiving rituximab for new onset type 1 diabetes.

Authors:  Jing Lu Kroll; Craig Beam; Shaobing Li; Raphael Viscidi; Bonnie Dighero; Alice Cho; David Boulware; Mark Pescovitz; Adriana Weinberg
Journal:  J Clin Virol       Date:  2013-02-17       Impact factor: 3.168

Review 8.  [Rituximab in treatment for neuroimmunological diseases].

Authors:  A Schröder; G Ellrichmann; G Chehab; M Schneider; R A Linker; R Gold
Journal:  Nervenarzt       Date:  2009-02       Impact factor: 1.214

Review 9.  Efficacy and safety of rituximab for myasthenia gravis: a systematic review and meta-analysis.

Authors:  Raffaele Iorio; Valentina Damato; Paolo Emilio Alboini; Amelia Evoli
Journal:  J Neurol       Date:  2014-10-12       Impact factor: 4.849

Review 10.  B cell depletion in autoimmune disease.

Authors:  Claire Gorman; Maria Leandro; David Isenberg
Journal:  Arthritis Res Ther       Date:  2003-10-02       Impact factor: 5.156
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.